In this study, we have developed biodegradable Fe
Introduction
Skin cancers are indeed the most common malignancy in humans. Chemotherapy is a common therapeutic modality for the treatment of skin cancers, but associated with multidrug-resistance of cancer cells and serious side effects, [1] [2] which result in poor prognoses for the patients.
To enhance therapeutic efficacy, multimodal treatments with chemotherapy and other therapeutic modalities including magnetic hyperthermia, photothermal therapy, and immunotherapy have been intensively studied. [3] [4] [5] [6] Among these studies, the combination of chemotherapy with magnetic hyperthermia shows a powerful potency. [7] [8] [9] [10] [11] [12] [13] [14] [15] Magnetic hyperthermia could treat the localized or deeply existing tumors without side effect by raising the temperature to 43-48 °C. [16] [17] Heat also increases the efficacy of different chemotherapeutic drugs at the hyperthermia temperature. 18 For example, Kim et al. reported magnetic iron oxide nanoparticles-conjugated polymeric micelles (MNP-PMs) as nanocarriers for combined chemotherapy and hyperthermia. 7 When the anticancer drug (doxorubicin, DOX) loaded MNP-PMs were used to treat human lung adenocarcinoma A549 cells in combination with hyperthermia under an alternating magnetic field (AMF), 78% of the cells were killed by the synergistic effect of heat and anticancer drugs, which was more effective than either chemotherapy or magnetic hyperthermia treatment alone. 7 Ren et al. investigated the efficiency of multifunctional Fe 3 O 4 magnetic nanoparticles (Fe 3 O 4 -MNP) with chemotherapy and hyperthermia for overcoming multidrug resistance in an in vivo model of leukemia. 8 The results showed that the anticancer drug-loaded Fe 3 O 4 -MNP not only increased tumor temperature during hyperthermia under an AMF, but also noticeably decreased P-glycoprotein and Bcl-2 expression and markedly increased Bax and caspase-3 expression. 8 Our group prepared magnetic mesoporous silica nanoparticles (MMSNs) for potential chemotherapy and magnetic hyperthermia. [9] [10] [11] [12] After capping with DNA on the DOX-loaded MMSNs, the DOX-MMSNs/DNA nanoparticles could efficiently generate heat to increase the temperature under an AMF, and thereby triggered the DOX release, which induced a higher efficacy to kill cancer cells. 10 However, treatments with nanoparticle-system are often repeated because cancer cells survive and continue to grow after the initial treatment. Furthermore, therapeutic nanosystems should be reinjected to achieve an adequate concentration in the tumor tissues for the following treatment due to rapid clearance of nanosystems from the tumor tissues. Multiple and frequent injections of therapeutic nanosystems could lead to patient pain or cause adverse side effects. Microneedles are microscale projections with the capability of delivering drugs to skin painlessly. [19] [20] [21] Also, microneedles can be designed to target specific layer of skin. For the treatment of skin cancers, microneedles are possible to arrive at tumor tissues, allowing for enhancing efficacy of therapeutic delivery. [22] [23] [24] [25] [26] For example, Wang et al. reported the microneedle patch-assisted immunotherapy that delivers anti-PD-1 (aPD1) for the enhanced treatment of the skin cancer. 22 The microneedle patch with biocompatible hyaluronic acid and pH-sensitive dextran nanoparticles can painlessly penetrate the epidermis and become submerged in the interstitial fluid to efficiently deliver aPD1 to the tumor microenvironment, which inhibited tumor growth superior to those obtained with intratumor injection of the same dose. 20 Donnelly et al. used silicon microneedle arrays to enhance skin penetration of porphyrin precursor 5-aminolevulinic acid (ALA) for photodynamic therapy, and in vivo experiments showed that microneedle puncture could reduce application time and ALA dose for high levels of the photosensitizer in skin. 23 Recently, Chen et al. developed a multifunctional microneedle system with the combination of chemotherapy and photothermal therapy, [24] [25] which consists of embeddable polycaprolactone (PCL) microneedles containing a photosensitive lanthanum hexaboride nanoparticles and an anticancer drug DOX. When applying microneedle system to treat mice bearing 4T1 breast tumors, the near-infrared light-activated heating and the DOX releasing behavior can be precisely controlled, and the microneedle-mediated synergistic therapy completely eradicated 4T1 tumors within 1 week. 25 Therefore, it can be speculated that the development of microneedles with the combination of chemotherapy and magnetic hyperthermia would achieve synergistic effect in the treatment of skin cancer. However, to the best of our knowledge, there are no previous reports describing the fabrication of magnetic microneedle systems with controlled drug delivery and magnetic hyperthermia for potential skin cancer therapy. Ltd. Ultrapure water was obtained from a Millipore pure water system. All chemicals were of analytical-reagent grade and used without further purification.
Fabrication of Fe 3 O 4 /PCL microneedles
Magnetic Fe 3 O 4 nanoparticles were synthesized according to the previously reported co-precipitation method. 9 All of the Fe 3 O 4 /PCL microneedle systems were fabricated using polydimethylsiloxane (PDMS) molds from Micropoint Technologies Pte, Ltd. Singapore. Each microneedle is of pyramidal shape, with 200 μm in width at the base, 600 μm in height, and a sharp tip tapering to 10 μm. The microneedles are arranged in a 10×1 0 array with 500 μm tip-to-tip spacing. First, a 20% (w/v) PCL+TMC solution was prepared by dissolving PCL and TMC in chloroform. Subsequently, a certain amount of Fe 3 O 4 nanoparticles and a model drug rhodamine B (RhB) were added to the PCL+TMC solution and then well mixed to obtain a homogeneous solution. The final amounts of different components in the microneedles and the sample names are listed in Table 1 .
After preparation of the mixture solution, a two-step casting process was used to fabricate the Fe 3 O 4 /PCL microneedles. Typically, 1.0 mL of the RhB/Fe 3 O 4 /(PCL+TMC) mixture solution was injected into each PDMS mold, followed by vacuum condition for 5 min to allow the mixture solution flow into the microneedle cavities. Afterward, the PDMS molds were centrifuged at rpm = 4000 for 20 min to compact the mixture into microneedle cavities, and the excess amounts of the mixture solution on the mold surface were removed for reuse.
To form a patch without the drug and Fe 3 O 4 nanoparticles, pure 20% (w/v) PCL solution was poured onto the filled mold, followed by further centrifugation at rpm=4000 and pressed with a piece of copper adhesive tape. Finally, the fully filled mold was dried at 25 °C for 24 h, and the drug-loaded Fe 3 O 4 /PCL microneedles were gently taken from the PDMS mold.
Mechanical strength test
Mechanical compression tests were performed using a universal testing machine (Zwick static materials testing machine (5 KN)). A microneedle array was placed on the flat rigid surface of a stainless steel base plate. An axial force was applied by a mount of a moving sensor, perpendicular to the axis of the microneedle array, at a constant speed of 5 μm s -1 . The initial distance from the tips of the microneedle arrays to the mount was set at 500 μm. The force was measured when the moving sensor touched the uppermost point of the microneedle array. The testing machine subsequently recorded the force required to move the mount as a function of microneedle displacement.
Magnetic heating ability of the Fe 3 O 4 /PCL microneedles
Magnetic heating abilities of the Fe 3 O 4 /PCL microneedles were evaluated using a DM100 System (NanoScale Biomagnetics, Spain) and the temperature was monitored with an optical fiber temperature sensor.
To evaluate magnetic heating abilities of the microneedles, we fabricated the microneedles containing a patch with drug and Fe 3 O 4 nanoparticles. Typically, 0.5 g of microneedles was placed in a testing vial with 1 mL water, and testing vial was heated under an AMF of 180 Gauss strength at 409 kHz frequency for 20 min. The upper limit of temperature was set to be 80 °C. The water temperature in testing vial was recorded and plotted as a function of the exposed time.
In vitro drug release from the Fe 3 O 4 /PCL microneedles
Rhodmine B (RhB) was used as a model drug, and the RhB loading amount was set to be 0.5 wt% to the weight of the PCL+TMC+Fe 3 O 4 mixture in this study. In vitro release of RhB from microneedles was evaluated through soaking microneedle system in PBS (pH = 7.4) at different temperature on an orbital shaker. The detailed process as follows: 1.0 g of microneedles was soaked in 4 mL of PBS at 37, 43 and 50 °C, respectively. At time intervals (10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h and 24 h), 50 μL of the released solution was withdrawn for analysis and replaced with 50 μL fresh PBS. The RhB concentrations in the released solutions were analyzed using a NanoDrop 2000C UV-Vis spectrophotometer. The percentages of the released RhB were calculated from the total RhB amount in the microneedles.
Results and discussion
Magnetic Fe 3 O 4 nanoparticles were synthesized by a co-precipitation method, and the crystalline structure can be easily indexed to Fe 3 O 4 according to the reflection peak positions and relative intensities on the wile-angle XRD pattern ( Figure 1A ). As depicted in TEM image, the particle size of Fe 3 O 4 nanoparticles was estimated to be 15~20 nm ( Figure 1B) , which is similar to the results in previous study, 9 endowing them with magnetic heating ability. In this study, magnetic Fe 3 O 4 nanoparticles were encapsulated in the PCL-based solution, and a two-step casting process was used to fabricate Fe 3 O 4 /PCL microneedles. For intradermal delivery of drugs from microneedles to specific sites, the Fe 3 O 4 /PCL microneedles must be strong enough to effectively penetrate the skin. In this study, mechanical compression tests were performed using a universal testing machine. previous studies demonstrated that the insertion force as low as 0.03 N/needle could result in 100% of microneedle penetrating the stratum corneum of skin in vitro. 28 Thus, the fabricated Fe 3 O 4 /PCL microneedles might enable complete insertion into the skin. To evaluate whether the Fe 3 O 4 /PCL microneedles have enough magnetic heating ability for hyperthermia therapy, the microneedles were placed in a testing vial with water and treated under an AMF with a magnetic field strength of 180 Gauss and a frequency of 409 kHz. When we fixed the 20 wt% Fe 3 O 4 nanoparticles in the microneedles, and changed the TMC from 10 to 30 wt% in the microneedles (MNs-3, MNs-5, MNs-6 and MNs-7 microneedles), the temperature increases for all types of microneedles were close to each other, which indicated that the heat generation was attributed to the encapsulated Fe 3 O 4 nanoparticles, and the TMC encapsulation did not influence the magnetic heating ability of the Fe 3 O 4 /PCL microneedles. On the other hand, the melting temperatures of TMC and PCL are 43-47 °C and 60 °C, respectively. That is to say, TMC and PCL can undergo rapid thermal transitions from a solid to liquid state when the Fe 3 O 4 /PCL microneedles are treated under an AMF. Therefore, it is possible to control the drug release rate through adjusting the percentages of Fe 3 O 4 nanoparticles and TMC.
To evaluate the feasibility of controlled drug release from the Fe 3 O 4 /PCL microneedles, rhodamine B (RhB) was used as a model drug and encapsulated with 0.5 wt% in each type of microneedles. Figure 6 shows the RhB release profiles from the Fe 3 O 4 /PCL microneedles without and with different Fe 3 O 4 nanoparticles and TMC in PBS at 37, 43 and 50 °C, respectively. It can be observed that all types of microneedles exhibited increased RhB release rate with increasing temperature. For example, MNs-6 microneedles released 36%, 45% and 49% of RhB within 24 h at 37, 43 and 50 °C, respectively ( Figure 6A ). It might be that the temperature increase could lead to thermal transitions of TMC and PCL due to their low melting temperatures, thus increasing the mobility of the polymer chains and monomers, and thereby accelerating the RhB diffusion.
On the other hand, at the same temperature, PCL microneedles (MNs-1) showed the lowest release rate and the encapsulation of Fe 3 O 4 nanoparticles and TMC in the microneedles could accelerate the RhB release rate. For example, the released percentages of RhB from the MNs-1, MNs-3 and MNs-6 microneedles at 50 °C were about 20%, 32% and 49%, respectively ( Figure 6A) . Furthermore, the encapsulation percentages of Fe 3 O 4 nanoparticles and TMC in the microneedles influenced the RhB release rate. The RhB release from the Fe 3 O 4 /PCL microneedles was slightly accelerated with increasing the encapsulation percentages of Fe 3 O 4 nanoparticles in the microneedles, but the increase of TMC percentages in the Fe 3 O 4 /PCL microneedles resulted in the significant increase for the RhB release rate ( Figure 6B ). The encapsulation of Fe 3 O 4 nanoparticles in the PCL microneedles could slightly increase the porosity of the microneedles, and thereby accelerate RhB release rate. While for the Fe 3 O 4 /PCL microneedles with TMC encapsulation, TMC is easy to melt due to the low melting temperature, and the TMC melting could increase the mobility of TMC, and accelerate the RhB release. More Fe 3 O 4 nanoparticles and TMC in the microneedles could induce higher porosity and mobility for RhB release. Thus, the encapsulation of Fe 3 O 4 nanoparticles and TMC with different percentages could control the RhB release rate.
Conclusions
In this study, biodegradable Fe 3 O 4 /PCL microneedles were developed for potential skin cancer treatment with transdermal controlled drug delivery and magnetic hyperthermia. The Fe 3 O 4 /PCL microneedles had enough mechanical strength to penetrate skin, and could generate heat to increase the temperature through adjusting the encapsulation amount of Fe 3 O 4 nanoparticles in the microneedles. Interestingly, the encapsulation of TMC in the Fe 3 O 4 /PCL microneedles enabled them with temperature-controlled drug release behavior and magnetic hyperthermia simultaneously. Therefore, the Fe 3 O 4 /PCL microneedles would be promising for skin cancer treatment with the potential combination of chemotherapy and magnetic hyperthermia.
